Research Square (Research Square),
Год журнала:
2023,
Номер
unknown
Опубликована: Сен. 7, 2023
Abstract
In
situ
tumor
vaccines
(ISTVs)
hold
great
potential
in
immunotherapy,
however,
three
major
obstacles,
including
inadequate
endogenous
antigen
uptake
by
dendritic
cells
(DCs),
weak
T-cell
immune
responses,
and
stubborn
immunosuppressive
microenvironment
(TME)
still
should
be
fully
addressed.
Herein,
a
trifecta
nanovaccine
(TriNV)
with
TME-responsive
transformable
ability
is
developed
to
tri-boost
antitumor
immunity.
First,
sufficient
tumor-associated
antigens
(TAAs)
were
liberated
after
immunogenic
cell
death
induced
TriNV-based
photoimmunotherapy.
Under
TME,
soft-transformed
TriNV
improved
the
of
TAAs
DCs
enhance
acquired
Second,
self-adjuvating
released
Mn2+
synergistically
promoted
DC
maturation
macrophage
M1
polarization
augmenting
stimulator
interferon
genes
(STING)
activation
further
amplify
responses.
Moreover,
decomposition
MnO2
within
core
exhausted
glutathione
(GSH)
facilitated
O2
release
alleviate
hypoxia
thereby
overcoming
chemical
obstacles
TME
mitigate
immunosuppression.
Thus,
remarkably
eradicated
primary
tumors
inhibited
distant
metastasis,
demonstrating
as
feasible
effective
ISTV
nanoplatform
for
combating
poorly
solid
tumors.
Bioactive Materials,
Год журнала:
2024,
Номер
36, С. 330 - 357
Опубликована: Март 11, 2024
Nanovaccines
have
gathered
significant
attention
for
their
potential
to
elicit
tumor-specific
immunological
responses.
Despite
notable
progress
in
tumor
immunotherapy,
nanovaccines
still
encounter
considerable
challenges
such
as
low
delivery
efficiency,
limited
targeting
ability,
and
suboptimal
efficacy.
With
an
aim
of
addressing
these
issues,
engineering
customized
through
modification
or
functionalization
has
emerged
a
promising
approach.
These
tailored
not
only
enhance
antigen
presentation,
but
also
effectively
modulate
immunosuppression
within
the
microenvironment.
Specifically,
they
are
distinguished
by
diverse
sizes,
shapes,
charges,
structures,
unique
physicochemical
properties,
along
with
ligands.
features
facilitate
lymph
node
accumulation
activation/regulation
immune
cells.
This
overview
bespoke
underscores
both
prophylactic
therapeutic
applications,
offering
insights
into
future
development
role
cancer
immunotherapy.
Advanced Functional Materials,
Год журнала:
2024,
Номер
34(26)
Опубликована: Янв. 9, 2024
Abstract
In
situ
tumor
vaccines
(ISTVs)
hold
great
potential
in
immunotherapy,
however,
three
major
obstacles,
including
inadequate
endogenous
antigen
uptake
by
dendritic
cells
(DCs),
weak
T‐cell
immune
responses,
and
stubborn
immunosuppressive
microenvironment
(TME),
still
need
to
be
fully
addressed.
Herein,
a
trifecta
nanovaccine
(TriNV)
with
TME‐responsive
transformable
ability
is
developed
tri‐boost
antitumor
immunity.
First,
sufficient
tumor‐associated
antigens
(TAAs)
are
liberated
after
immunogenic
cell
death
induced
via
TriNV‐based
photoimmunotherapy.
the
TME,
soft‐transformed
TriNV
improves
of
TAAs
DCs
enhance
acquired
Second,
self‐adjuvating
released
Mn
2+
synergistically
promote
DC
maturation
macrophage
M1
polarization
augmenting
stimulator
interferon
genes
activation
further
amplify
responses.
Moreover,
decomposition
MnO
2
within
core
exhausts
glutathione
facilitates
O
release
alleviate
hypoxia
thereby
overcoming
chemical
obstacles
TME
mitigate
immunosuppression.
Thus,
remarkably
eradicates
primary
tumors
inhibits
distant
metastasis,
thus
demonstrating
as
feasible
effective
ISTV
nanoplatform
for
combating
poorly
solid
tumors.
ACS Nano,
Год журнала:
2024,
Номер
18(43), С. 29439 - 29456
Опубликована: Окт. 15, 2024
The
stimulator
of
interferon
genes
(STING)
pathway
is
crucial
for
tumor
immunity,
leading
to
the
exploration
STING
agonists
as
potential
immunotherapy
adjuvants.
However,
their
clinical
application
faces
obstacles
including
poor
pharmacokinetics,
transient
activation,
and
an
immunosuppressive
microenvironment
(TME).
Addressing
these
limitations,
our
study
aims
develop
injectable
silk
fibroin
hydrogel-based
in
situ
vaccine.
It
incorporates
a
nanoscale
agonist,
immunogenic
cell
death
(ICD)
inducer,
immunomodulator
ensure
controlled
sustained
release.
cGAMP
nanoparticles
(cGAMPnps)
with
core–shell
structure
optimal
delivery
dendritic
cells
(DCs),
thereby
activating
fostering
DC
maturation.
ICD-associated
damage-associated
molecular
patterns
amplify
prolong
activation
via
enhanced
type
I
IFN
other
inflammatory
pathways,
along
delayed
degradation
STING.
Furthermore,
STING-driven
vascular
normalization
by
cGAMPnps
ICD,
conjunction
immunomodulators
like
antiprogrammed
protein
1
antibody
(anti-PD-1
Ab)
or
OX40
ligand
(OX40L),
effectively
remodels
TME.
This
gel
vaccine,
when
used
independently
surgery
neoadjuvant/adjuvant
immunotherapy,
enhances
CD8+
T-cell
suppressing
progression
recurrence
across
various
immunologically
cold
models.
revolutionizes
cancer
offering
substantial
promise
improving
outcomes
broad
spectrum
malignancies.
Biomaterials Research,
Год журнала:
2025,
Номер
29
Опубликована: Янв. 1, 2025
Tumors
are
the
second
most
common
cause
of
mortality
globally,
ranking
just
below
heart
disease.
With
continuous
advances
in
diagnostic
technology
and
treatment
approaches,
survival
rates
some
cancers
have
increased.
Nevertheless,
due
to
complexity
mechanisms
underlying
tumors,
cancer
remains
a
serious
public
health
issue
that
threatens
population
globally.
Manganese
(Mn)
is
an
essential
trace
element
for
human
body.
Its
regulatory
role
tumor
biology
has
received
much
attention
recent
years.
Developments
nanotechnology
led
emergence
Mn-based
nanoparticles
great
potential
use
diagnosis
cancers.
nanomaterials
can
be
integrated
with
conventional
techniques,
including
chemotherapy,
radiation
therapy,
gene
augment
their
therapeutic
effectiveness.
Further,
play
synergistic
emerging
strategies
such
as
immunotherapy,
photothermal
photodynamic
electromagnetic
hyperthermia,
sonodynamic
chemodynamic
intervention
therapy.
Moreover,
enhance
both
precision
diagnostics
capability
combined
treatment.
This
article
examines
roles
associated
Mn
field
physiology
biology,
focus
on
application
prospects
